Citranvi Biosciences is focused on developing prophylactic vaccines aimed at preventing diseases caused by latent viral pathogens, particularly herpesviruses such as Human Cytomegalovirus (HCMV) and Epstein-Barr Virus (EBV). The company is in the pre-clinical stage and is engaged in creating innovative vaccine technology platforms that utilize comprehensive structure-based vaccine design. This approach is intended to enhance immunogenicity and is applicable to a range of preventable diseases where there is a significant unmet medical need. Citranvi's collaboration with the Henry M. Jackson Foundation for the Advancement of Military Medicine underscores its commitment to addressing the challenges posed by these viral infections, which can remain latent in the host and reactivate, leading to various health complications.

The company's lead products include the Global Multiantigen HCMV Vaccine and the Global Multiantigen EBV Vaccine. The HCMV vaccine targets women of childbearing age to prevent congenital infections, which can lead to severe birth defects and significant economic costs. Meanwhile, the EBV vaccine aims to reduce the incidence of infectious mononucleosis and its associated risks, particularly in adolescents and high-risk populations such as organ transplant recipients. Both vaccines are designed to mitigate the health impacts of these viruses, which are prevalent globally and can lead to serious long-term health issues, including various cancers and autoimmune diseases.

United States

Citranvi Biosciences is a pre-clinical stage company engaged in the design and development of novel systems and tools for immunogenicity enhancement applicable to Vaccines Research and Development.  We are developing innovative and proprietary vaccine technology platforms and products, using comprehensive structure-based vaccine design, broadly applicable to a variety of preventable disease targets, where there is an unmet global medical need. 

Citranvi Biosciences

Company Details